Hypertension. Treatment of essential hypertension in adults. Prevention of cardiovascular diseases. Reducing the incidence of cardiovascular disease in patients with: pronounced manifestations of atherothrombotic cardiovascular disease (ischemic heart disease, stroke or peripheral artery disease in history); type II diabetes mellitus with diagnosed target organ damage.
Composition and form of release
Telmisartan-Teva is produced in the form of oblong tablets from white to almost white in color, on one side they have a break line.
The active ingredient of the drug is telmisartan 80 mg. As additional components in the composition are designated: sorbitol, hypromellose, lures, meglumine, sodium hydroxide, povidone, magnesium stearate.
One carton pack contains 4 blisters, each containing 7 tablets.
Telmisartan-Teva is an antihypertensive drug that is used for therapy in essential hypertension. The maximum positive effect is observed after 1-2 months of treatment. The antihypertensive effect after taking the drug lasts for a day. Telmisartan-Teva lowers blood pressure within 3 hours after administration, without changing the heart rate.
Telmisartan-Teva is intended for use in the case of essential hypertension in adult patients, and for the prevention of cardiovascular diseases in patients with type II diabetes mellitus, as well as with obvious manifestations of atherothrombotic cardiovascular disease (peripheral arterial disease or stroke, coronary artery disease). hearts).
Telmisartan-Teva is contraindicated for use in severe liver dysfunction, bile duct diseases and hypersensitivity to substances that are part of the tablets. Simultaneous administration with aliskiren is contraindicated in patients with impaired renal function or diabetes mellitus and do not prescribe the drug to children under 18 years of age.
Application during pregnancy and lactation
The drug Telmisartan-Teva is contraindicated for pregnant, lactating and planning pregnancy women.
Method of administration and dosage
Telmisartan-Teva tablets must be taken regardless of food, drinking plenty of fluids.
The recommended daily dose of Telmisartan-Teva is 40 mg. For some patients, a dose of 20 mg once a day is possible. If blood pressure is not sufficiently reduced at this dosage, then it can be increased to 80 mg per day.
Telmisartan Teva can be taken in combination with other antihypertensive drugs.
The most effective antihypertensive effect is achieved after 1-2 months of treatment.
In the prevention of cardiovascular diseases, the recommended dose is 80 mg 1 time per 24 hours.
The maximum allowable dose is 80 mg per day.
Symptoms in case of an overdose with Telmisartan-Teva may be: arterial hypotension, fainting, tachycardia, increased serum creatinine, bradycardia, acute renal failure. In case of intoxication, it is necessary to take activated charcoal, further treatment depends on the elapsed time after taking the drug and on the severity of the character and symptoms. The drug is not excreted by hemodialysis.
The use of Telmisartan-Teva can cause many adverse reactions such as: upper respiratory tract and urinary tract infections, sepsis, including death, anemia, eosinophilia and thrombocytopenia, anaphylactic reactions, hypersensitivity, hypoglycemia and hyperkalemia, depression, anxiety, insomnia, syncope, blurred vision, drowsiness.
Treatment with the drug can lead to: vertigo, bradycardia, arterial hypotension, tachycardia and shortness of breath, chest and abdominal pain, diarrhea, dyspepsia, vomiting, indigestion and flatulence, impaired renal and liver function, eczema and dermatitis, urticaria. Also possible: myalgia, cough, muscle cramps, pain in the limbs and tendons, arthralgia, asthenia, dry mouth, decreased hemoglobin levels, increased levels of creatinine, uric acid and liver enzymes in the blood.
Storage conditions and periods
The Telmisartan-Teva drug must be stored out of the reach of children, at a temperature that does not exceed + 25 ° C, in its original packaging. The shelf life of the tablets is 36 months. Prescription only.